VERAXA Biotech (NASDAQ: VRXA) has announced a significant milestone in its oncology pipeline: the VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase into the next stage of development. This progress follows the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work concluded, VERAXA will now focus on engineering the final therapeutic candidate by combining the antibody binders identified through the collaboration with its proprietary antibody engineering, linker, and conjugation technologies.
Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's core expertise in antibody engineering and conjugation, positioning it as one of VERAXA's more advanced development programs. The company is responsible for building the final bispecific ADC candidate and advancing preclinical validation, a critical step toward potential clinical trials.
In parallel with the VXA-222 advancement, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP estate is designed to safeguard VERAXA's innovative approaches and provide a competitive edge in the rapidly evolving field of antibody-based cancer therapies.
The VXA-222 milestone and IP expansion underscore VERAXA's commitment to building a diversified oncology pipeline that spans bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. By advancing VXA-222 and strengthening its patent portfolio, VERAXA is positioning itself to deliver next-generation therapies that could address significant unmet medical needs in oncology.
The company's progress reflects its strategic focus on leveraging proprietary technologies to develop novel cancer treatments. As VERAXA continues to advance its pipeline, stakeholders will be watching for further developments, including preclinical results and potential regulatory interactions. The expansion of the patent portfolio not only protects the company's innovations but also enhances its attractiveness to potential partners and investors.
For more information on VERAXA and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA. Forward-looking statements in this announcement are subject to risks and uncertainties, as detailed in VERAXA's filings with the SEC.
